Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748357 | 0.86 | CCR1 (0.48) | TDP1CCR1S1PR4HTR3AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL28688823 | 0.86 | KDM4E (0.39) | TDP1CCR1S1PR4ERN1KDM4E | |
| SCHEMBL11517006 | 0.81 | S1PR4 (0.45) | TDP1S1PR4HTR3AHRH4KDM4E | |
| SCHEMBL14912331 | 0.78 | KDM4E (0.45) | TDP1HTR3AHRH4ALDH1A1KDM4E | |
| SCHEMBL14912329 | 0.78 | KDM4E (0.45) | TDP1HTR3AHRH4ALDH1A1KDM4E | |
| SCHEMBL13456148 | 0.77 | CCR1 (0.47) | CCR1S1PR4ERN1ALDH1A1KDM4E | |
| SCHEMBL1914989 | 0.77 | BACE1 (0.53) | CCR1ALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL10740204 | 0.77 | CYP1A2 (0.57) | CCR1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2278668 | 0.77 | CCR1 (0.47) | CCR1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1002564 | 0.77 | BACE1 (0.53) | CCR1ERN1ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024052692-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023231948-A1 | ISR INHIBITORS, METHOD FOR PREPARING SAME, AND USE THEREOF | 中国药科大学 | 2023-12-07 | — | — | WO | disclosed |
| CN-116768877-A | ISR inhibitor and preparation method and application thereof | 中国药科大学 | 2023-09-19 | — | — | CN | disclosed |
| WO-2018080065-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 주식회사 두산 | 2018-05-03 | — | — | WO | disclosed |
| US-9657034-B2 | Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors | AbbVie Deuschland GmbH & Co. KG (DE) | 2017-05-23 | — | — | US | disclosed |
| EP-2776418-B1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-01-04 | — | — | EP | disclosed |
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-05-19 | — | — | US | disclosed |
| US-9273068-B2 | Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-03-01 | — | — | US | disclosed |
| EP-2937341-A1 | 4-(BENZYL)-PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | Janssen Pharmaceutica N.V. (BE) | 2015-10-28 | — | — | EP | disclosed |
| EP-2937341-A1 | 4-(BENZYL)-PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | Janssen Pharmaceutica N.V. (BE) | 2015-10-28 | — | — | EP | disclosed |
| WO-2006074025-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006038989-A1 | SUBSTITUTED ARYLAMIDES | CHEMOCENTRYX, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074071-A1 | Substituted arylamides | CHEMOCENTRYX, INC. (US) | 2006-04-06 | — | — | US | disclosed |
| EP-1575925-A1 | NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2005-09-21 | — | — | EP | disclosed |
| US-20050154039-A1 | 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine | IPSEN PHARMA S.A.S. (FR) | 2005-07-14 | — | — | US | disclosed |
| CN-1617859-A | 5-sulfanyl-4H-1, 2, 4-triazole derivatives and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2005-05-18 | — | — | CN | disclosed |
| US-20040220169-A1 | Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-11-04 | — | — | US | disclosed |
| EP-1465880-A1 | 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004056784-A1 | NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003045926-A1 | 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHE ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE3B | TDP1 62/4885CCR1 1062/4885S1PR4 1390/4885 |
| US-20060074071-A1 | Substituted arylamides | AADAC, BRDT, BRPF3 | TDP1 2556/4885CCR1 4599/4885S1PR4 2776/4885 |
| US-20050154039-A1 | 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine | SSTR3, SSTR1, SSTR5 | TDP1 4177/4885CCR1 391/4885S1PR4 134/4885 |
| US-20040220169-A1 | Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions | F12, F11, F2 | TDP1 1062/4885CCR1 906/4885S1PR4 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.